BioStem insider acquires 17,196 shares via RSUs
BioStem’s COO and ten percent owner converted 17,196 RSUs into common shares and retains substantial option and RSU awards.
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) insider Andrew Smith-Van Vurst, a director, Chief Operating Officer and ten percent owner, exercised restricted stock units into common stock on September 15 and September 17, 2026. He converted 7,622 and 9,574 restricted stock units, respectively, into an equal number of common shares at a stated price of $0.00 per share, with corresponding RSU positions disposed of. No open-market purchases or sales are reported, and no Rule 10b5-1 trading plan is indicated. He continues to hold significant equity awards, including multiple option grants and 209,091 restricted stock units tied to future vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
17,196 shares exercised/converted
Exercise
9 txns
Insider
SMITH-VAN VURST ANDREW
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F5, F7 | 9,574 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,574 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F5, F6 | 7,622 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,622 | $0.00 | $0.00 |
| holding | Options (Right to Buy) F1 | -- | -- | -- |
| holding | Options (Right to Buy) F2 | -- | -- | -- |
| holding | Options (Right to Buy) F3 | -- | -- | -- |
| holding | Options (Right to Buy) F4 | -- | -- | -- |
| holding | Restricted Stock Units F5, F8 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 297,020 contracts for 209,091 underlying shares (Direct);
Common Stock — 1,539,809 shares (Direct);
Options (Right to Buy) — 2,640,864 contracts (Direct)
Footnotes (8)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F6. These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
RSUs converted to common stock on September 15, 2026: 7,622 shares
RSUs converted to common stock on September 17, 2026: 9,574 shares
Total RSUs exercised in reported transactions: 17,196 shares
+5 more
8 metrics
RSUs converted to common stock on September 15, 2026
7,622 shares
RSUs exercised into common stock at $0.00 per share
RSUs converted to common stock on September 17, 2026
9,574 shares
RSUs exercised into common stock at $0.00 per share
Total RSUs exercised in reported transactions
17,196 shares
Combined RSU conversions on September 15 and 17, 2026
Options (Right to Buy) at $2.00
2,250,000 underlying shares
Exercise price $2.00; expiration October 24, 2032; direct ownership
Options (Right to Buy) at $10.05 expiring March 17, 2035
114,314 underlying shares
Exercise price $10.05; expiration March 17, 2035; direct ownership
Options (Right to Buy) at $10.05 expiring October 13, 2035
23,246 underlying shares
Exercise price $10.05; expiration October 13, 2035; direct ownership
Options (Right to Buy) at $5.50
253,304 underlying shares
Exercise price $5.50; expiration February 11, 2036; direct ownership
Restricted stock units outstanding
209,091 underlying shares
Each RSU is a contingent right to one share; vesting begins February 11, 2027 with quarterly installments
Key Terms
Restricted Stock Units, Options (Right to Buy), contingent right, equal quarterly installments, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Options (Right to Buy) financial
"Options (Right to Buy) with specified exercise prices and expiration dates"
contingent right financial
"represents a contingent right to receive one share of the issuer's common stock"
equal quarterly installments financial
"remaining options vesting in equal quarterly installments over the subsequent two year period"
ten percent owner regulatory
"reporting person is identified as a ten percent owner of the issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioStem Technologies (BSEM) insider Andrew Smith-Van Vurst report in this Form 4?
He reported exercising restricted stock units into 17,196 shares of BioStem common stock on September 15 and 17, 2026, with no open-market purchases or sales disclosed and corresponding RSU positions reduced.
Were the BioStem (BSEM) Form 4 transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for these RSU exercises and resulting share acquisitions.
What option positions does Andrew Smith-Van Vurst retain in BioStem (BSEM) after these transactions?
He retains options over 2,250,000 underlying shares at $2.00 expiring October 24, 2032; 114,314 shares at $10.05 expiring March 17, 2035; 23,246 shares at $10.05 expiring October 13, 2035; and 253,304 shares at $5.50 expiring February 11, 2036.
How many restricted stock units in BioStem (BSEM) does Andrew Smith-Van Vurst still hold and how do they vest?
He holds 209,091 restricted stock units, each representing a contingent right to one common share. A related footnote states 33% will vest on February 11, 2027, with the remaining units vesting in equal quarterly installments over the subsequent two-year period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
